Genital Diseases, Female
Welcome,         Profile    Billing    Logout  
 271 Companies   374 Products   374 Products   160 Mechanisms of Action   34 Trials   5514 News 


«12...5556575859606162636465...110111»
  • ||||||||||  Ovidrel (choriogonadotropin alfa) / EMD Serono
    Trial completion, Enrollment change:  Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) -  Dec 12, 2014   
    P3,  N=24, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Nov 2016 --> Apr 2015 Recruiting --> Completed | N=75 --> 24
  • ||||||||||  clindamycin phosphate / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  TUPAC: Treatment Utility of Postpartum Antibiotics in Chorioamnionitis (clinicaltrials.gov) -  Dec 10, 2014   
    P4,  N=80, Terminated, 
    Trial primary completion date: Oct 2014 --> Jul 2015 N=238 --> 80 | Recruiting --> Terminated | Trial primary completion date: Jul 2013 --> Jul 2014; Futility in patient enrollment
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  FAST-L: Fibroid Ablation Study - Large Fibroids (clinicaltrials.gov) -  Dec 10, 2014   
    P=N/A,  N=6, Terminated, 
    N=50 --> 4 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jun 2014; Investigational device changes N=48 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Jun 2014; Investigational device changes
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  FAST-EU: Fibroid Ablation Study (clinicaltrials.gov) -  Dec 10, 2014   
    P=N/A,  N=51, Terminated, 
    N=48 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Jun 2014; Investigational device changes N=100 --> 51 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Mar 2014; Investigational device changes; adequate enrollment achieved
  • ||||||||||  Truseltiq (infigratinib) / BridgeBio, Pfizer, Helsinn, Xediton Pharma
    New P1 trial, Combination therapy, Metastases:  Ph Ib/BGJ398/Cervix and Other Solid Tumors (clinicaltrials.gov) -  Dec 10, 2014   
    P1,  N=24, Not yet recruiting, 
  • ||||||||||  Trial completion, Trial primary completion date:  Risk Assessment of Long-Haul Truck Drivers (clinicaltrials.gov) -  Dec 10, 2014   
    P=N/A,  N=294, Completed, 
    N=100 --> 51 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Mar 2014; Investigational device changes; adequate enrollment achieved Recruiting --> Completed | Trial primary completion date: Aug 2010 --> Mar 2010
  • ||||||||||  Trial completion:  Molecular Associations With Reproductive Failure (clinicaltrials.gov) -  Dec 9, 2014   
    P=N/A,  N=475, Completed, 
    Phase classification: P=N/A --> P4 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  X-Chromosome Inactivation Status and Premature Ovarian Failure (clinicaltrials.gov) -  Dec 9, 2014   
    P=N/A,  N=13, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 13 | Trial primary completion date: Nov 2008 --> Oct 2009
  • ||||||||||  Trial initiation date:  Community-Driven Cervical Cancer Prevention in Western Kenya (clinicaltrials.gov) -  Dec 7, 2014   
    P=N/A,  N=7200, Not yet recruiting, 
    Active, not recruiting --> Completed | N=30 --> 9 Initiation date: Jul 2014 --> Feb 2015
  • ||||||||||  Enrollment closed, Preclinical:  Clinical Measures of Ovarian Reserve in Predicting IVF Success (clinicaltrials.gov) -  Dec 6, 2014   
    P=N/A,  N=300, Active, not recruiting, 
    N=626 --> 146 | Recruiting --> Terminated Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Trial primary completion date:  Safer Sex Program for Young African-American Men (clinicaltrials.gov) -  Dec 6, 2014   
    P2,  N=620, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> May 2018
  • ||||||||||  metformin / Generic mfg.
    Phase classification:  Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET) (clinicaltrials.gov) -  Dec 6, 2014   
    P1/2,  N=150, Recruiting, 
    N=20 --> 115 | Recruiting --> Terminated | Trial primary completion date: Apr 2009 --> Oct 2012; Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) has been replaced by other system Phase classification: P1 --> P1/2
  • ||||||||||  Trial primary completion date:  Hysteroscopic Assessment of Fallopian Tubal Patency (clinicaltrials.gov) -  Dec 5, 2014   
    P=N/A,  N=500, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Apr 2016
  • ||||||||||  Jevtana (cabazitaxel) / Sanofi, Emcure
    Enrollment change, Trial termination, Trial primary completion date:  Cabazitaxel in Platinum Refractory Ovarian Cancer (clinicaltrials.gov) -  Dec 5, 2014   
    P2,  N=4, Terminated, 
    N=40 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Jul 2014; Too low inclusion rate. Only 4 patients included over 16 months
  • ||||||||||  zoliflodacin (ETX0914) / Entasis Therap, Global Antibiotic Research and Development Partnership
    Enrollment open:  Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea (clinicaltrials.gov) -  Dec 5, 2014   
    P2,  N=180, Recruiting, 
    Only 4 patients included over 16 months Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Improving Knowledge About Infertility; an Online Educational Tool (clinicaltrials.gov) -  Dec 5, 2014   
    P=N/A,  N=72, Completed, 
    Active, not recruiting --> Completed Not yet recruiting --> Completed | N=100 --> 72 | Trial primary completion date: Oct 2013 --> Sep 2014
  • ||||||||||  Trial completion, Enrollment change:  Effects of Early Abuse on Adult Intimate Relationships (clinicaltrials.gov) -  Dec 5, 2014   
    P=N/A,  N=148, Completed, 
    Not yet recruiting --> Completed | N=100 --> 72 | Trial primary completion date: Oct 2013 --> Sep 2014 Active, not recruiting --> Completed | N=300 --> 148
  • ||||||||||  Elonva (corifollitropin alfa) / Organon
    Trial completion, Enrollment change, Trial primary completion date:  D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists (clinicaltrials.gov) -  Dec 5, 2014   
    P4,  N=67, Completed, 
    Active, not recruiting --> Completed | N=300 --> 148 Recruiting --> Completed | N=50 --> 67 | Trial primary completion date: Dec 2012 --> Mar 2013
  • ||||||||||  Trial completion, Enrollment change:  SHAPE: Sexual Health on Antidepressants Through Physical Exercise (clinicaltrials.gov) -  Dec 5, 2014   
    P=N/A,  N=52, Completed, 
    Recruiting --> Completed | N=50 --> 67 | Trial primary completion date: Dec 2012 --> Mar 2013 Active, not recruiting --> Completed | N=75 --> 52
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion, Trial primary completion date:  Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma (clinicaltrials.gov) -  Dec 5, 2014   
    P2,  N=36, Completed, 
    Active, not recruiting --> Completed | N=75 --> 52 Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> May 2012